Injectable testosterone cypionate/anastrozole lacks sterility assurance
Vita Pharmacy, LLC dba Talon Compounding Pharmacy is recalling injectable testosterone cypionate 200mg/anastrozole 0.75mg/ml due to lack of assurance of sterility. The recall affects specific lots distributed across the United States, Washington D.C., and Puerto Rico.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The source text identifies this as an FDA Class II recall. Lack of sterility assurance in injectable products poses a significant risk of serious adverse health effects including infection, bacteremia, and sepsis. Although no specific illnesses or hospitalizations are reported in the source text, the inherent hazard of non-sterile injectables warrants a Severe classification per the rubric's Class II criterion.
Plain-English summary
Vita Pharmacy, LLC dba Talon Compounding Pharmacy is recalling TESTOSTERONE CYPIONATE 200MG/ANASTROZOLE 0.75MG/ML IN OIL INJECTABLE (Rx only) due to lack of assurance of sterility.
The affected product was distributed throughout the United States, including Washington D.C. and Puerto Rico. The recall involves four vials from two specific lots: Lot T1008032021:52 with a beyond-use date of 01/30/2022, and Lot T1008192021:96 with a beyond-use date of 02/15/2022.
Consumers who have received this product should contact their healthcare provider or pharmacist for guidance. Individuals should not use the recalled product.
For additional information, patients and healthcare providers can contact the FDA or the recalling firm.
The recalled product
- Product
- TESTOSTERONE CYPIONATE 200MG/ANASTROZOLE 0.75MG/ML IN OIL INJECTABLE, Rx only, Talon Compounding Pharmacy, 2950 Thousand Oaks Drive Ste 25, San Antonio, Texas 78247
- Manufacturer
- Vita Pharmacy, LLC dba Talon Compounding Pharmacy
- Category
- Drug — Injectable / Compounded
- Hazard
- lack-of-sterility
- injection-infection-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot: T1008032021:52 BUD: 01/30/2022
- T1008192021:96 BUD: 02/15/2022
Distribution
Distribution scope not specified by the agency.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27